A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata

PHASE3RecruitingINTERVENTIONAL
Enrollment

225

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

April 20, 2027

Study Completion Date

May 18, 2027

Conditions
Severe Alopecia Areata
Interventions
DRUG

Ritlecitinib higher dose

Study intervention will be provided as oral capsules centrally by the sponsor in high-density polyethylene (HDPE) bottles.

DRUG

Ritlecitinib lower dose

Study intervention will be provided as oral capsules centrally by the sponsor in HDPE bottles.

DRUG

Placebo

Study intervention will be provided as oral capsules centrally by the sponsor in HDPE bottles.

Trial Locations (17)

33156

RECRUITING

Pediatric Skin Research, Miami

33321

RECRUITING

D&H Tamarac Research Center, Tamarac

46250

RECRUITING

Dawes Fretzin Clinical Research Group, LLC, Indianapolis

68046

RECRUITING

Complete Behavior Health (Dr. Brittany Marshall, Licensed Psychologist), Papillion

68144

RECRUITING

Ear, Nose and Throat Consultants, LLC, Omaha

RECRUITING

Skin Specialists, PC dba Schlessinger MD, Omaha

78218

RECRUITING

Texas Dermatology and Laser Specialists, San Antonio

78660

RECRUITING

Austin Institute for Clinical Research, Pflugerville

79902

RECRUITING

3A Research - West Location, El Paso

84041

NOT_YET_RECRUITING

AMR Clinical, Layton

97210

RECRUITING

Northwest Dermatology Institute, Portland

200040

NOT_YET_RECRUITING

Huashan Hospital, Fudan University, Shanghai

980-8574

RECRUITING

Tohoku University Hospital, Sendai

951-8520

RECRUITING

Niigata University Medical & Dental Hospital, Niigata

431-3192

RECRUITING

Hamamatsu University Hospital, Hamamatsu

181-8611

NOT_YET_RECRUITING

Kyorin University Hospital, Mitaka

545-8586

RECRUITING

Osaka Metropolitan University Hospital, Osaka

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY